National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- (-) Adverse Drug Events (ADE) (20)
- Adverse Events (9)
- Antibiotics (2)
- Behavioral Health (1)
- Blood Clots (1)
- Blood Thinners (4)
- Cancer: Colorectal Cancer (1)
- Cardiovascular Conditions (5)
- Care Management (1)
- Children/Adolescents (1)
- Chronic Conditions (2)
- Comparative Effectiveness (4)
- Dementia (1)
- Elderly (1)
- Evidence-Based Practice (10)
- Heart Disease and Health (6)
- Medicaid (1)
- Medication (18)
- Medication: Safety (1)
- Neurological Disorders (2)
- Nursing Homes (1)
- Opioids (1)
- Outcomes (4)
- Pain (1)
- Patient-Centered Healthcare (1)
- (-) Patient-Centered Outcomes Research (20)
- Patient Safety (2)
- Registries (1)
- Respiratory Conditions (1)
- Risk (5)
- Stroke (1)
- Substance Abuse (1)
- Treatments (2)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 20 of 20 Research Studies DisplayedVilla Zapata L, Hansten PD, Panic J
Risk of bleeding with exposure to warfarin and nonsteroidal anti-inflammatory drugs: a systematic review and meta-analysis.
Warfarin use can trigger the occurrence of bleeding independently or as a result of a drug-drug interaction when used in combination with nonsteroidal anti-inflammatory drugs (NSAIDs). This article examines the risk of bleeding in individuals exposed to concomitant warfarin and NSAID compared with those taking warfarin alone. The investigators concluded that risk of bleeding was significantly increased among persons taking warfarin and a NSAID or COX-2 inhibitor together as compared with taking warfarin alone.
AHRQ-funded; HS025984.
Citation: Villa Zapata L, Hansten PD, Panic J .
Risk of bleeding with exposure to warfarin and nonsteroidal anti-inflammatory drugs: a systematic review and meta-analysis.
Thromb Haemost 2020 Jul;120(7):1066-74. doi: 10.1055/s-0040-1710592..
Keywords: Blood Thinners, Medication, Medication: Safety, Risk, Adverse Drug Events (ADE), Adverse Events, Patient Safety, Evidence-Based Practice, Patient-Centered Outcomes Research, Outcomes
Fink HA, Linskens EJ, MacDonald R
Benefits and harms of prescription drugs and supplements for treatment of clinical Alzheimer-type dementia
This is a systematic review and meta-analysis of the benefits and harms of prescription drugs and supplements for treatment of clinical Alzheimer-type dementia (CATD). Studies with low or medium risk of bias (ROB) were analyzed and rated. The analysis concluded there was a slight reduction in short-term cognitive decline with cholinesterase inhibitors and memantime, and cholinesterase inhibitors slightly reduced reported functional decline. There was mostly insufficient evidence on drug treatment of behavioral and psychological symptoms of dementia and on supplements for all outcomes.
AHRQ-funded; 290201500008I.
Citation: Fink HA, Linskens EJ, MacDonald R .
Benefits and harms of prescription drugs and supplements for treatment of clinical Alzheimer-type dementia
Ann Intern Med 2020 May 19;172(10):656-68. doi: 10.7326/m19-3887..
Keywords: Elderly, Dementia, Neurological Disorders, Medication, Patient-Centered Outcomes Research, Evidence-Based Practice, Outcomes, Adverse Drug Events (ADE), Adverse Events, Treatments
Samples H, Williams AR, Crystal S
Impact of long-term buprenorphine treatment on adverse health care outcomes In Medicaid.
The optimal, or even minimum, duration of medication treatment for opioid use disorder (OUD) needed to improve long-term outcomes has not been established empirically. As a result, health plans set potentially restrictive treatment standards to guide benefits and payment. To address this gap, the investigators used a National Quality Forum measure for OUD medication treatment duration (180 days) to examine the impact of longer treatment on health care outcomes within a key population of Medicaid enrollees.
AHRQ-funded; HS023258; HS021112.
Citation: Samples H, Williams AR, Crystal S .
Impact of long-term buprenorphine treatment on adverse health care outcomes In Medicaid.
Impact of long-term buprenorphine treatment on adverse health care outcomes In Medicaid..
Keywords: Medication, Substance Abuse, Opioids, Medicaid, Adverse Drug Events (ADE), Adverse Events, Patient-Centered Outcomes Research, Evidence-Based Practice, Outcomes
Dobler CC, Morrow AS, Beuschel B
Pharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease: a systematic review with meta-analysis.
The authors evaluated the comparative effectiveness and adverse events of pharmacologic interventions for adults with exacerbation of COPD. Sixty-eight randomized controlled trials were selected for evaluation and data extraction. They found that antibiotics and systemic corticosteroids reduced treatment failure in adults with mild to severe exacerbation of COPD.
AHRQ-funded.
Citation: Dobler CC, Morrow AS, Beuschel B .
Pharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease: a systematic review with meta-analysis.
Ann Intern Med 2020 Mar 17;172(6):413-23. doi: 10.7326/m19-3007..
Keywords: Respiratory Conditions, Chronic Conditions, Evidence-Based Practice, Patient-Centered Outcomes Research, Comparative Effectiveness, Medication, Antibiotics, Treatments, Adverse Drug Events (ADE), Adverse Events
Patek TM, Teng C, Kennedy KE
Comparing acute kidney injury reports among antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
A study using the US FDA Adverse Event Reporting System (FAERS) found significant acute kidney injury (AKI) reporting associations with vancomycin, fluoroquinolones, penicillin combinations, and trimethoprim-sulfamethoxazole. Other antibiotics may also lead to AKI, but no study has systemically compared AKI reporting associations for many available antibiotics. The objective of this study was to evaluate the reporting associations between AKI and many available antibiotics using FAERS.
AHRQ-funded; HS022418.
Citation: Patek TM, Teng C, Kennedy KE .
Comparing acute kidney injury reports among antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
Drug Saf 2020 Jan;43(1):17-22. doi: 10.1007/s40264-019-00873-8..
Keywords: Adverse Drug Events (ADE), Adverse Events, Antibiotics, Medication, Patient-Centered Outcomes Research, Outcomes
Lowenstern A, Al-Khatib SM, Sharan L
Interventions for preventing thromboembolic events in patients with atrial fibrillation: a systematic review.
The purpose of this review was to compare the effectiveness of therapies to prevent thromboembolic events and bleeding complications in adults with nonvalvular atrial fibrillation (AF). Two independent reviewers screened citations in order to identify comparative studies of treatments to prevent stroke in adults with nonvalvular AF who reported thromboembolic or bleeding complications, then abstracted data from 220 selected articles, assessed study quality and applicability, and rated the strength of evidence. The article concludes that available direct-acting oral anticoagulants (DOACs) are at least as effective and safe as warfarin for patients with nonvalvular AF and had similar benefits across several patient subgroups.
AHRQ-funded; 290201500004I.
Citation: Lowenstern A, Al-Khatib SM, Sharan L .
Interventions for preventing thromboembolic events in patients with atrial fibrillation: a systematic review.
Ann Intern Med 2018 Dec 4;169(11):774-87. doi: 10.7326/m18-1523..
Keywords: Cardiovascular Conditions, Heart Disease and Health, Blood Thinners, Adverse Drug Events (ADE), Adverse Events, Medication, Comparative Effectiveness, Patient-Centered Outcomes Research, Evidence-Based Practice
Borre ED, Goode A, Raitz G
Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review.
This systematic review compared the strength of tools to predict stroke and bleeding risk in patients with atrial fibrillation (AF) taking blood thinners. Sixty-one studies were found to predict thromboembolic risk and 38 to predict bleeding risk.
AHRQ-funded; 290201500004I.
Citation: Borre ED, Goode A, Raitz G .
Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review.
Thromb Haemost 2018 Dec;118(12):2171-87. doi: 10.1055/s-0038-1675400..
Keywords: Heart Disease and Health, Cardiovascular Conditions, Stroke, Blood Clots, Blood Thinners, Medication, Adverse Drug Events (ADE), Adverse Events, Risk, Patient-Centered Outcomes Research, Evidence-Based Practice
Leonard CE, Brensinger CM, Aquilante CL
Comparative safety of sulfonylureas and the risk of sudden cardiac arrest and ventricular arrhythmia.
This study examined the association between individual antidiabetic sulfonylureas and outpatient-originating sudden cardiac arrest and ventricular arrhythmia (SCA/VA). It concluded that glyburide may be associated with a lower risk of SCA/VA than glipizide, consistent with a very small clinical trial suggesting that glyburide may reduce ventricular tachycardia and isolated ventricular premature complexes.
AHRQ-funded; HS023898.
Citation: Leonard CE, Brensinger CM, Aquilante CL .
Comparative safety of sulfonylureas and the risk of sudden cardiac arrest and ventricular arrhythmia.
Diabetes Care 2018 Apr;41(4):713-22. doi: 10.2337/dc17-0294.
.
.
Keywords: Adverse Drug Events (ADE), Cardiovascular Conditions, Medication, Patient-Centered Outcomes Research, Patient Safety
Klinge M, Coppler T, Liebschutz JM
The assessment and management of pain in cirrhosis.
The treatment of pain in patients with cirrhosis is complicated by unpredictable hepatic drug metabolism and a higher risk of adverse drug reactions. The researchers aimed to conduct a scoping review regarding pain management in cirrhosis. As with other populations, a multi-dimensional treatment approach to pain with a focus on physical, behavioral, procedural and pharmacologic treatment is recommended when caring for patients with cirrhosis and pain.
AHRQ-funded; HS022989.
Citation: Klinge M, Coppler T, Liebschutz JM .
The assessment and management of pain in cirrhosis.
Curr Hepatol Rep 2018 Mar;17(1):42-51. doi: 10.1007/s11901-018-0389-7.
.
.
Keywords: Adverse Drug Events (ADE), Care Management, Chronic Conditions, Evidence-Based Practice, Medication, Pain, Patient-Centered Outcomes Research
Ng X, dosReis S, Beardsley R
Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids.
This qualitative study examined systemic lupus erythematosus (SLE) patients' most desired outcomes and their concerns with corticosteroid use in SLE treatment. The SLE patients' most desired outcomes: reduction in flares, maintenance of normal activities, minimization of treatment side effects, prevention of future organ damage, and finding a cure. The patients’ primary concerns with the adverse effects of corticosteroids: weight gain, organ damage, mood swings/irritability, sleep disturbances, and dental issues.
AHRQ-funded; HS022135.
Citation: Ng X, dosReis S, Beardsley R .
Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids.
Lupus 2018 Mar;27(3):475-83. doi: 10.1177/0961203317726375.
.
.
Keywords: Adverse Drug Events (ADE), Medication, Patient-Centered Outcomes Research
Smith I, Schmidt R, Halm EA
Do statins increase the risk of esophageal conditions? Findings from four propensity score-matched analyses.
The aim of this study was to examine the association of statins with esophageal conditions. The study concluded that statin therapy was associated with higher odds of being diagnosed with esophagitis and gastroesophageal reflux disease/dyspepsia. Further study is warranted to elucidate the potential role of statins in these commonly diagnosed esophageal conditions.
AHRQ-funded; HS022418.
Citation: Smith I, Schmidt R, Halm EA .
Do statins increase the risk of esophageal conditions? Findings from four propensity score-matched analyses.
Clin Drug Investig 2018 Feb;38(2):135-46. doi: 10.1007/s40261-017-0589-x..
Keywords: Adverse Drug Events (ADE), Heart Disease and Health, Medication, Patient-Centered Outcomes Research, Risk
Bykov K, Schneeweiss S, Glynn RJ
Updating the evidence of the interaction between clopidogrel and CYP2C19-inhibiting selective serotonin reuptake inhibitors: a cohort study and meta-analysis.
The aim of this study was to assess clinical outcomes following initiation of a CYP2C19-inhibiting selective serotonin reuptake inhibitor (SSRI) versus initiation of other SSRIs among patients treated with clopidogrel and to update existing evidence on the clinical impact of clopidogrel-SSRI interaction. It concluded that the updated evidence still indicates a small decrease in clopidogrel effectiveness associated with concomitant exposure to clopidogrel and CYP2C19-inhibiting SSRIs.
AHRQ-funded; HS023122.
Citation: Bykov K, Schneeweiss S, Glynn RJ .
Updating the evidence of the interaction between clopidogrel and CYP2C19-inhibiting selective serotonin reuptake inhibitors: a cohort study and meta-analysis.
Drug Saf 2017 Oct;40(10):923-32. doi: 10.1007/s40264-017-0556-8.
.
.
Keywords: Adverse Drug Events (ADE), Medication, Evidence-Based Practice, Patient-Centered Outcomes Research
Steinman MA, Zullo AR, Lee Y
Association of β-blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction.
The researchers studied the association of beta-blockers after AMI with functional decline, mortality, and rehospitalization among long-stay nursing home residents 65 years or older. Use of beta-blockers after AMI was associated with functional decline in older nursing home residents with substantial cognitive or functional impairment, but not in those with relatively preserved mental and functional abilities.
AHRQ-funded; HS022998.
Citation: Steinman MA, Zullo AR, Lee Y .
Association of β-blockers with functional outcomes, death, and rehospitalization in older nursing home residents after acute myocardial infarction.
JAMA Intern Med 2017 Feb;177(2):254-62. doi: 10.1001/jamainternmed.2016.7701.
.
.
Keywords: Nursing Homes, Patient-Centered Outcomes Research, Medication, Adverse Drug Events (ADE), Heart Disease and Health
Bavishi AA, Grammer LC, Pongracic J
Diurnal variations in subcutaneous allergen immunotherapy reactions.
The investigators sought to assess whether the timing of subcutaneous immunotherapy (SCIT) affects the rate of adverse reactions. They found that afternoon and evening injections of SCIT are associated with increased cutaneous reaction rates when compared with morning injections, recommending the administration of SCIT in the morning in patients experiencing bothersome local reactions.
AHRQ-funded; HS023011.
Citation: Bavishi AA, Grammer LC, Pongracic J .
Diurnal variations in subcutaneous allergen immunotherapy reactions.
Ann Allergy Asthma Immunol 2017 Jan;118(1):103-07. doi: 10.1016/j.anai.2016.10.007.
.
.
Keywords: Adverse Drug Events (ADE), Medication, Patient-Centered Healthcare, Patient-Centered Outcomes Research
Linden S, Bussing R, Kubilis P
Risk of suicidal events with atomoxetine compared to stimulant treatment: a cohort study.
The researchers analyzed whether the observed increased risk of suicidal ideation in clinical trials translates into an increased risk of suicidal events in pediatric patients treated with atomoxetine compared with stimulants in 26 Medicaid programs. They found that first- and second-line treatment of youths age 5 to 18 with atomoxetine compared with stimulants was not significantly associated with an increased risk of suicidal events.
AHRQ-funded; HS018506; HS016097.
Citation: Linden S, Bussing R, Kubilis P .
Risk of suicidal events with atomoxetine compared to stimulant treatment: a cohort study.
Pediatrics 2016 May;137(5):pii: e20153199. doi: 10.1542/peds.2015-3199.
.
.
Keywords: Adverse Drug Events (ADE), Medication, Children/Adolescents, Comparative Effectiveness, Patient-Centered Outcomes Research
Nierenberg AA, McElroy SL, Friedman ES
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder.
The purpose of this trial was to compare lithium and second-generation antipsychotics. The investigators found that outcomes with lithium + APT and quetiapine + APT were not significantly different across 6 months of treatment for bipolar disorder.
AHRQ-funded; HS019371.
Citation: Nierenberg AA, McElroy SL, Friedman ES .
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder.
J Clin Psychiatry 2016 Jan;77(1):90-9. doi: 10.4088/JCP.14m09349.
.
.
Keywords: Adverse Drug Events (ADE), Comparative Effectiveness, Medication, Behavioral Health, Patient-Centered Outcomes Research
Du XL, Zhang Y
Risks of venous thromboembolism, stroke, heart disease, and myelodysplastic syndrome associated with hematopoietic growth factors in a large population-based cohort of patients with colorectal cancer.
This study sought to determine the relationship between the receipt of colony-stimulating factors (CSFs) with erythropoiesis-stimulating agents (ESAs) and the risk of developing venous thromboembolism (VTE), stroke, heart disease, and myelodysplastic syndrome (MDS) in patients with colorectal cancer. It found that the use of ESAs was significantly associated with a substantially increased risk of MDS in patients with colorectal cancer.
AHRQ-funded; HS018956.
Citation: Du XL, Zhang Y .
Risks of venous thromboembolism, stroke, heart disease, and myelodysplastic syndrome associated with hematopoietic growth factors in a large population-based cohort of patients with colorectal cancer.
Clin Colorectal Cancer 2015 Dec;14(4):e21-31. doi: 10.1016/j.clcc.2015.05.007.
.
.
Keywords: Adverse Drug Events (ADE), Cancer: Colorectal Cancer, Cardiovascular Conditions, Patient-Centered Outcomes Research, Risk
O'Brien EC, Simon DN, Thomas LE
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
The researchers sought to develop and validate a novel bleeding risk score using routinely available clinical information to predict major bleeding in a large, community-based in atrial fibrillation (AF) population. They concluded that their five-element ORBIT bleeding risk score had better ability to predict major bleeding in AF patients when compared with HAS-BLED and ATRIA risk scores.
AHRQ-funded; HS021092.
Citation: O'Brien EC, Simon DN, Thomas LE .
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
Eur Heart J 2015 Dec 7;36(46):3258-64. doi: 10.1093/eurheartj/ehv476.
.
.
Keywords: Blood Thinners, Heart Disease and Health, Cardiovascular Conditions, Adverse Drug Events (ADE), Adverse Events, Risk, Registries, Patient-Centered Outcomes Research, Evidence-Based Practice
Desai NR, Sabatine MS
PCSK9 inhibition in patients with hypercholesterolemia.
The authors specified that large, cardiovascular outcomes trials are underway to assess definitively the efficacy and safety of 3 monoclonal antibodies (evolocumab, alirocumab, and bococizumab), while additional non-monoclonal antibody approaches to inhibit PCSK9 continue in the early-phase development.
AHRQ-funded; HS023000.
Citation: Desai NR, Sabatine MS .
PCSK9 inhibition in patients with hypercholesterolemia.
Trends Cardiovasc Med 2015 Oct;25(7):567-74. doi: 10.1016/j.tcm.2015.01.009.
.
.
Keywords: Adverse Drug Events (ADE), Heart Disease and Health, Evidence-Based Practice, Medication, Patient-Centered Outcomes Research
Ott BR, Daiello LA, Dahabreh IJ
Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials.
The researchers aimed to synthesize randomized clinical trial (RCTs) evidence on the association between statin therapy and cognitive outcomes. Their meta-analysis of cognitive test data from 14 studies failed to show significant adverse effects of statins on all tests of cognition in either cognitively normal subjects or Alzheimer’s disease subjects.
AHRQ-funded; HS017735.
Citation: Ott BR, Daiello LA, Dahabreh IJ .
Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials.
J Gen Intern Med 2015 Mar;30(3):348-58. doi: 10.1007/s11606-014-3115-3..
Keywords: Adverse Drug Events (ADE), Adverse Events, Medication, Neurological Disorders, Patient-Centered Outcomes Research